CN1157372C - 二氢茚基取代的苯甲酰胺、其制备方法、其作为药物的应用、和含有它们的药物制剂 - Google Patents

二氢茚基取代的苯甲酰胺、其制备方法、其作为药物的应用、和含有它们的药物制剂 Download PDF

Info

Publication number
CN1157372C
CN1157372C CNB008094500A CN00809450A CN1157372C CN 1157372 C CN1157372 C CN 1157372C CN B008094500 A CNB008094500 A CN B008094500A CN 00809450 A CN00809450 A CN 00809450A CN 1157372 C CN1157372 C CN 1157372C
Authority
CN
China
Prior art keywords
hydrogen
carbon atoms
formula
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008094500A
Other languages
English (en)
Chinese (zh)
Other versions
CN1358172A (zh
Inventor
J���¶���
J·布兰德尔
U·格兰克
���ٶ���԰�������޹�˾
H·U·斯蒂尔兹
H-J·兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1358172A publication Critical patent/CN1358172A/zh
Application granted granted Critical
Publication of CN1157372C publication Critical patent/CN1157372C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/26—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNB008094500A 1999-06-25 2000-06-10 二氢茚基取代的苯甲酰胺、其制备方法、其作为药物的应用、和含有它们的药物制剂 Expired - Fee Related CN1157372C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19929076A DE19929076A1 (de) 1999-06-25 1999-06-25 Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE19929076.8 1999-06-25

Publications (2)

Publication Number Publication Date
CN1358172A CN1358172A (zh) 2002-07-10
CN1157372C true CN1157372C (zh) 2004-07-14

Family

ID=7912468

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008094500A Expired - Fee Related CN1157372C (zh) 1999-06-25 2000-06-10 二氢茚基取代的苯甲酰胺、其制备方法、其作为药物的应用、和含有它们的药物制剂

Country Status (31)

Country Link
US (1) US6221866B1 (enExample)
EP (1) EP1194403B1 (enExample)
JP (1) JP4527918B2 (enExample)
KR (1) KR20020023962A (enExample)
CN (1) CN1157372C (enExample)
AR (1) AR024443A1 (enExample)
AT (1) ATE248811T1 (enExample)
AU (1) AU771601B2 (enExample)
BR (1) BR0011938A (enExample)
CA (1) CA2377087A1 (enExample)
CZ (1) CZ20014523A3 (enExample)
DE (2) DE19929076A1 (enExample)
DK (1) DK1194403T3 (enExample)
EE (1) EE04464B1 (enExample)
ES (1) ES2200886T3 (enExample)
HK (1) HK1047575B (enExample)
HU (1) HUP0201711A3 (enExample)
IL (1) IL147220A0 (enExample)
MX (1) MXPA01012281A (enExample)
NO (1) NO20015816D0 (enExample)
NZ (1) NZ516347A (enExample)
PL (1) PL352985A1 (enExample)
PT (1) PT1194403E (enExample)
RU (1) RU2238934C2 (enExample)
SI (1) SI1194403T1 (enExample)
SK (1) SK19092001A3 (enExample)
TR (1) TR200103701T2 (enExample)
TW (1) TWI256950B (enExample)
WO (1) WO2001000573A1 (enExample)
YU (1) YU88801A (enExample)
ZA (1) ZA200109732B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6970362B1 (en) 2000-07-31 2005-11-29 Intel Corporation Electronic assemblies and systems comprising interposer with embedded capacitors
US6775150B1 (en) 2000-08-30 2004-08-10 Intel Corporation Electronic assembly comprising ceramic/organic hybrid substrate with embedded capacitors and methods of manufacture
JP2004509894A (ja) 2000-09-20 2004-04-02 ファルマシア・アンド・アップジョン・カンパニー 置換アゼピノ［４，５−ｂ］インドリン誘導体
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) * 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
WO2004086865A1 (en) 2003-03-27 2004-10-14 Cytokinetics, Inc. Compounds, compositions and methods
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US7368582B2 (en) 2003-10-17 2008-05-06 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
JPWO2007023775A1 (ja) * 2005-08-23 2009-02-26 アステラス製薬株式会社 心房細動治療剤
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CN101636154B (zh) * 2006-04-27 2011-12-14 塞诺菲-安万特德国有限公司 Task-1和task-3离子通道抑制剂
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
WO2008098025A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Arylsulfonamide compounds which modulate the cb2 receptor
JP4891111B2 (ja) * 2007-02-16 2012-03-07 富士フイルム株式会社 ズームレンズ
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
EP2217565B1 (en) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2326629B1 (en) * 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CA2737645A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2480544A1 (en) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (enExample) 2011-07-01 2018-04-28
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4110317B1 (en) 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2023211855A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising a thiophene core and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234944A (en) 1986-08-21 1993-08-10 Roussel Uclaf Novel indanes
ES2052593T3 (es) 1986-08-21 1994-07-16 Roussel Uclaf Procedimiento para preparar derivados del indano.
DK626889A (da) 1988-12-16 1990-06-17 Roussel Uclaf Indanderivater, deres fremstilling samt laegemidler med indhold deraf
US5348971A (en) 1988-12-16 1994-09-20 Roussel Uclaf Indanes useful as analgesics
RU2043337C1 (ru) * 1990-07-20 1995-09-10 Институт биохимии Литовской АН Способ получения 5-аргиниламинонафталин-1-сульфамидов
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
EP0738149B1 (en) * 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindan derivatives and compositions thereof
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DE19707656A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
AU8684598A (en) * 1997-08-05 1999-03-01 American Home Products Corporation Anthranilic acid analogs
DE19749453A1 (de) * 1997-11-10 1999-05-12 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte anellierte 5-Ring-Verbindungen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
NZ516347A (en) 2004-01-30
US6221866B1 (en) 2001-04-24
IL147220A0 (en) 2002-08-14
EE200100684A (et) 2003-04-15
ZA200109732B (en) 2002-08-30
HUP0201711A3 (en) 2005-05-30
TWI256950B (en) 2006-06-21
CA2377087A1 (en) 2001-01-04
DE19929076A1 (de) 2000-12-28
AR024443A1 (es) 2002-10-02
KR20020023962A (ko) 2002-03-29
PL352985A1 (en) 2003-09-22
SK19092001A3 (sk) 2002-06-04
HUP0201711A2 (en) 2002-09-28
CN1358172A (zh) 2002-07-10
AU771601B2 (en) 2004-03-25
WO2001000573A1 (de) 2001-01-04
BR0011938A (pt) 2002-03-19
SI1194403T1 (en) 2003-12-31
NO20015816L (no) 2001-11-29
NO20015816D0 (no) 2001-11-29
MXPA01012281A (es) 2002-07-30
PT1194403E (pt) 2004-01-30
CZ20014523A3 (cs) 2002-04-17
YU88801A (sh) 2004-09-03
HK1047575B (zh) 2004-12-31
DE50003555D1 (de) 2003-10-09
ES2200886T3 (es) 2004-03-16
TR200103701T2 (tr) 2002-05-21
HK1047575A1 (en) 2003-02-28
JP2003503385A (ja) 2003-01-28
RU2238934C2 (ru) 2004-10-27
JP4527918B2 (ja) 2010-08-18
EP1194403B1 (de) 2003-09-03
ATE248811T1 (de) 2003-09-15
DK1194403T3 (da) 2003-12-08
EP1194403A1 (de) 2002-04-10
AU5531800A (en) 2001-01-31
EE04464B1 (et) 2005-04-15

Similar Documents

Publication Publication Date Title
HK1047575A1 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
CN1225463C (zh) 具有钾通道阻断作用的芳基化呋喃和噻吩甲酰胺
CN1290825C (zh) 邻位、间位取代的双芳基化合物、它们的制备方法、它们作为药物的用途和含有它们的药物制剂
CN1237052C (zh) 用作钾通道抑制剂的邻位取代的含氮双芳基化合物
CN1522244A (zh) 邻氨基苯甲酰胺类化合物、其制备方法、其作为抗心律不齐剂的应用及其药物制剂
CN100335461C (zh) 芳基磺酰基苯胺脲
EP0558657B1 (en) Retroviral protease inhibitors
CN1019571B (zh) 制备新的联二苯正丙胺衍生物及其盐的方法
CN1478081A (zh) 取代的2-苯胺基苯并咪唑及其作为nhe抑制剂的用途
CN1062555C (zh) 取代的苄氧羰基胍、其制备方法、作为药剂或诊断剂的应用以及含有它的药剂
CN1326928A (zh) 联苯磺酰基氨基氰、其制备方法及其作为药物的用途
CN1111618A (zh) 脲取代的苯甲酰胍、制法和用途及含苯甲酰胍的药物
CN1177827C (zh) 联苯基磺酰基取代的咪唑类衍生物、其制备方法、其作为药物或诊断剂的应用和含有它们的药物
CN1216763A (zh) 磺酰胺取代的苯并二氢吡喃,其制备方法,其作为药物的用途以及含有它们的药物制剂
CN1211370C (zh) 具有联苯基磺酰基取代基的咪唑衍生物、其制备方法及其作为药物或诊断剂的应用
CN1219533A (zh) 磺酰胺取代的稠合5－元环化合物,其作为药物的应用,以及包含它们的药物组合物
JP2012506418A (ja) テトラヒドロナフタレン化合物
CN1060162C (zh) 取代的苯磺酰脲和苯磺酰硫脲、其制备方法、制备药物制剂的用途和含有它们的药品
CN1218050A (zh) 磺酰胺取代的苯并吡喃衍生物,其制备方法及其作为药物的用途,以及包含它们的药物制剂
CN1173960C (zh) 取代六元氮杂环类化合物及其作为神经调节剂的用途
CN101076526A (zh) 三环胍衍生物用作钠－质子交换抑制剂
CN1227010C (zh) 取代的四氢异喹啉衍生物的用途
CN1125444A (zh) 新型的二氮杂萘衍生物，它们的制备方法和含有它们的尤其用作抗增生药的药物组合物
HK1019586A (en) Sulfonamide-substituted fused 5-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
CN1193012A (zh) 氨磺酰取代的化合物、其制备方法、它们作为药物或诊断剂的用途以及含有它们的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1047575

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: SANOFI- AVENTIS GERMAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Frankfurt, Germany

Patentee after: AVENTIS PHARMA DEUTSCHLAND GmbH

Address before: Frankfurt, Germany

Patentee before: AVENTIS PHARMA DEUTSCHLAND GmbH

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee